Cancer treatment and research communications最新文献

{"title":"Characterization of POU2F3-expressing large cell neuroendocrine carcinoma of the lung: A comprehensive analysis of morphology, immunohistochemistry, and genomic alterations","authors":"Ryota Matsuoka ,&nbsp;Kei Asayama ,&nbsp;Tomoki Nakagawa ,&nbsp;Yoshihiko Murata ,&nbsp;Ayako Suzuki ,&nbsp;Yutaka Suzuki ,&nbsp;Naohiro Kobayashi ,&nbsp;Yukio Sato ,&nbsp;Nobuyuki Hizawa ,&nbsp;Hiroyoshi Tsubochi ,&nbsp;Shunsuke Endo ,&nbsp;Koichi Hagiwara ,&nbsp;Toshiro Niki ,&nbsp;Noriyoshi Fukushima ,&nbsp;Kentaro Inamura ,&nbsp;Daisuke Matsubara","doi":"10.1016/j.ctarc.2026.101113","DOIUrl":"10.1016/j.ctarc.2026.101113","url":null,"abstract":"<div><div>Large cell neuroendocrine carcinoma (LCNEC) is a neuroendocrine carcinoma (NEC) of the lung that is characterized by its heterogeneous morphology, diverse immunophenotypes, and complex genomic profiles. Among LCNECs, a subset expressing the transcription factor POU2F3 (LCNEC-P) has been suggested to share similarities with small cell lung carcinoma (SCLC)-P, a subtype of SCLC defined by POU2F3 expression. However, the specific characteristics of LCNEC-P have not been fully elucidated. Therefore, the aim of the present study is to clarify the clinicopathological, immunohistochemical, and genetic characteristics of LCNEC-P.</div><div>Fifty-six LCNEC cases were analyzed, including 12 LCNEC-P and 44 LCNEC-non-P cases. Morphologically, LCNEC-P exhibited significantly lower cytomorphology scores, indicating a resemblance to SCLC. Immunohistochemically, LCNEC-P showed the lower expression of neuroendocrine markers (SYP, CHGA, and INSM1), but the higher expression of C-MYC than LCNEC-non-P. A strong mutually exclusive expression pattern was observed between POU2F3 and ASCL1/NEUROD1. Whole-genome sequencing of 20 cases revealed that LCNEC-P harbored <em>RB1</em> mutations in 100 % of cases, which was significantly higher than in LCNEC-non-P (40 %). <em>FGFR1</em> amplification was observed in 60 % of LCNEC-P cases, representing a higher prevalence than previously reported for LCNEC. In addition, LCNEC-P showed a distinct copy number alteration profile, including frequent 20q13 amplification, compared with LCNEC-non-P.</div><div>These results demonstrate that LCNEC-P represents a distinct subgroup of LCNEC that is characterized by a specific morphological, immunohistochemical, and genetic profile, closely resembling SCLC-P. This study provides insights into the biology of LCNEC-P and supports its classification as a unique entity within LCNEC.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"46 ","pages":"Article 101113"},"PeriodicalIF":2.4,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146022991","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Chemotherapy-induced liver injury in Tibetan breast cancer patients: clinical features and risk factor analysis","authors":"Quzhen Ciren ,&nbsp;Zhen Se ,&nbsp;Wangmu Sangdan ,&nbsp;Puchi Suolang ,&nbsp;Yulan Zhao ,&nbsp;Yiqun Li ,&nbsp;Yuchao Ma","doi":"10.1016/j.ctarc.2026.101111","DOIUrl":"10.1016/j.ctarc.2026.101111","url":null,"abstract":"<div><h3>Objective</h3><div>To conduct the first analysis of the clinical characteristics and factors affecting drug-induced liver injury following neoadjuvant and adjuvant chemotherapy for breast cancer in the Xizang region.</div></div><div><h3>Methods</h3><div>Overall, 246 patients with breast cancer diagnosed and treated at the People's Hospital of Tibet Autonomous Region from June 2016 to August 2023 were retrospectively analyzed, among whom 71 patients received neoadjuvant or adjuvant chemotherapy. Liver injury was defined as elevated levels of alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, or total bilirubin beyond the upper limit of normal from the initiation of chemotherapy to 3 months post-chemotherapy. The severity was assessed according to Common Terminology Criteria for Adverse Events v5.0. Cases with alternative etiologies, such as viral hepatitis reactivation, were excluded. Factors influencing drug-induced liver injury were analyzed. A univariate analysis was conducted using the chi-square test, whereas a multivariate analysis was performed using logistic regression. The difference was considered statistically significant at p&lt;0.05.</div></div><div><h3>Results</h3><div>The median age of all patients was 51 years (range, 28–71 years). Liver injury was observed in 37 cases (52.1%), and 89.2% of them had Grade I-II injury. Both univariate and multivariate analyses suggested that receiving concomitant anti-HER-2 targeted therapy (OR=6.290, 95%CI: 1.617-24.472, p=0.008) was a risk factor for chemotherapy-induced liver injury.</div></div><div><h3>Conclusion</h3><div>Receiving concurrent anti-HER-2 targeted therapy is a major risk factor for post-chemotherapy liver function injury for patients with breast cancer in the Xizang region, and the monitoring of liver function levels should be strengthened in such patients.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"46 ","pages":"Article 101111"},"PeriodicalIF":2.4,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146073561","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical characteristics and survival outcomes of young women with luminal HER2-low and HER2-ultralow breast cancer","authors":"Jesus Edgardo Hernandez-Hernandez ,&nbsp;César Octavio Lara-Torres ,&nbsp;Alejandro Aranda-Gutierrez ,&nbsp;Víctor A. Domínguez-Porras ,&nbsp;Bryan Moreno-Moran ,&nbsp;Héctor Díaz-Pérez ,&nbsp;Gabriela Sofía Gómez-Macías ,&nbsp;Cynthia Villarreal-Garza ,&nbsp;Alejandro Mohar","doi":"10.1016/j.ctarc.2026.101112","DOIUrl":"10.1016/j.ctarc.2026.101112","url":null,"abstract":"<div><h3>Background</h3><div>Young women with breast cancer (YWBC) often present with aggressive, hormone receptor-positive tumors. However, the implications of HER2-low and HER2-ultralow expression in this group have not been well characterized despite their potential therapeutic relevance.</div></div><div><h3>Methods</h3><div>We conducted a retrospective study of 157 Mexican women aged ≤ 40 years with a prior diagnosis of luminal, HER2-negative breast cancer. HER2 status was reassessed to characterize different levels of HER2 expression within HER2-negative disease, specifically HER2-null, HER2-low, and HER2-ultralow. Clinicopathological features and survival outcomes were compared across groups.</div></div><div><h3>Results</h3><div>Evaluation of HER2 expression levels identified that 21.0 % of tumors met criteria for HER2-low expression and 18.5 % for HER2-ultralow expression. HER2-low tumors were more prevalent in luminal B disease and were associated with higher Ki-67, lower PR, and increased tumor-infiltrating lymphocytes, while there were no particularities in HER2-null and ultralow tumors. No significant differences were observed in disease-free or overall survival between HER2-null, HER2-low, and HER2-ultralow groups.</div></div><div><h3>Conclusions</h3><div>Approximately 40 % of young women with luminal HER2-negative breast cancers have HER2-low or ultralow disease. These findings highlight the importance of accurately assessing HER2 expression in YWBC to identify candidates for emerging HER2-targeted therapies such as trastuzumab deruxtecan.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"46 ","pages":"Article 101112"},"PeriodicalIF":2.4,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146073562","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Circular RNAs as emerging regulators of mitochondrial function and disease","authors":"Mehrzad Esmaeili Niasan ,&nbsp;Soudeh Ghafouri-Fard","doi":"10.1016/j.ctarc.2026.101165","DOIUrl":"10.1016/j.ctarc.2026.101165","url":null,"abstract":"<div><div>Circular RNAs (circRNAs) are a class of covalently closed, non-coding RNAs that have emerged as regulators of gene expression and cellular homeostasis. Accumulating evidence shows that circRNAs are involved in the regulation of mitochondrial function, energy metabolism, and stress responses. Dysregulation of circRNAs has been linked to a wide range of mitochondrial-associated diseases, including neurodegenerative disorders, metabolic syndromes, cardiovascular diseases, and cancers. This review summarizes current knowledge on mitochondrial-related circRNAs, their biogenesis, molecular mechanisms, and pathophysiological roles, with a focus on their potential as diagnostic biomarkers and therapeutic targets.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"47 ","pages":"Article 101165"},"PeriodicalIF":2.4,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147385876","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A population-based analysis of the elective surgical management for non-metastatic splenic flexure cancers, the ongoing question","authors":"Ahmed Zeid,&nbsp;Mariana Morales-Cruz,&nbsp;Ahmed Almonib,&nbsp;Stephen Thomas Ward","doi":"10.1016/j.ctarc.2026.101318","DOIUrl":"10.1016/j.ctarc.2026.101318","url":null,"abstract":"<div><h3>Aim and background</h3><div>Malignancies found at the splenic flexure correspond to only 2–4% of all colorectal cancers and no standardised surgical technique exists for its treatment. Our study analyses the surgical and oncological outcomes between Extended Right Hemicolectomy (ERH) and Left Hemicolectomy (LH), the operations commonly performed to resect tumours in this location.</div></div><div><h3>Methodology</h3><div>A retrospective cohort study of patients with non metastatic splenic flexure cancer treated between 1997 and 2017 within the NHS in England. The surgical approach was defined through OPCS-4 codes. Patients were divided into two different categories depending on the type of surgery performed (ERH vs LH). A number of post-operative and oncological outcomes were compared.</div></div><div><h3>Results</h3><div>Around 1 690 of the cases were treated with LH, while 1 992 had an ERH. ERH was performed more commonly in younger patients (p = 0.002) and it was significantly associated with longer hospital stay, more frequent return to theatre (p= &lt;0.0001) and higher 90-day mortality rate (p = 0.0361). The lymph node yield was significantly greater for ERH when compared to LH (p &lt; 0.001) but there were no significant differences in survival (p = 0.877).</div></div><div><h3>Conclusions</h3><div>Lymph node yield is greater in ERH compared to LH yet this is not reflected in improved survival. LH appears to have some advantages in terms of improved post-operative outcomes. Important patient outcomes, such as bowel function, could not be measured.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"48 ","pages":"Article 101318"},"PeriodicalIF":3.5,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148547921","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comprehensive molecular profiling of advanced NSCLC in Greek patients:A prospective HeCOG study","authors":"Paris A. Kosmidis,&nbsp;Thanos Kosmidis,&nbsp;Kyriaki Papadopoulou,&nbsp;Nikolaos Korfiatis,&nbsp;Athanasios Vozikis,&nbsp;Sofia Lampaki,&nbsp;Panagiota Economopoulou,&nbsp;Elena Fountzila,&nbsp;Athina Christopoulou,&nbsp;Epaminondas Samantas,&nbsp;Anastasios Vagionas,&nbsp;Giannis Socrates Mountzios,&nbsp;Georgios Gkoumas,&nbsp;Nikolaos Tsoukalas,&nbsp;Ilias Athanasiadis,&nbsp;Dimitris Bafaloukos,&nbsp;Chris Panopoulos,&nbsp;Margarita Ioanna Koufaki,&nbsp;George Petrakis,&nbsp;Georgios Fountzilas,&nbsp;Helena Linardou","doi":"10.1016/j.ctarc.2026.101310","DOIUrl":"10.1016/j.ctarc.2026.101310","url":null,"abstract":"<div><h3>Background</h3><div>We report for the first time the molecular landscape and outcome associations from the prospective CLIMEDIN trial in Greece.</div></div><div><h3>Methods</h3><div>Two hundred patients with newly diagnosed advanced NSCLC (March 2022–October 2023) were enrolled and randomized to standard-of-care education versus additional automated, adverse-event–targeted digital interventions. Within this study baseline testing (EGFR, ALK, PD-L1) was performed in all; 165 tumors underwent comprehensive NGS (Oncomine Comprehensive Assay v3). Primary endpoint was improvement in AEs/QoL; secondary endpoints included ORR, PFS and OS. Associations between genomic alterations and outcomes were explored.</div></div><div><h3>Results</h3><div>Median age was 68 years; 75% male; 52% current smokers; adenocarcinoma 68.5%. Most received chemo-immunotherapy (66%). At data cut-off (December 2025; reverse-Kaplan–Meier median follow-up 36.3 months), median PFS was 9.6 months and median OS was 15.2 months. Across 200 tumors, 495 pathogenic variants (PVs) were identified in 83 genes. Exploratory outcome analyses showed longer OS in EGFR-mutant disease (preserved under parsimonious multivariable adjustment) and a formal KRAS × smoking interaction for OS (interaction P = 0.011).</div></div><div><h3>Conclusions</h3><div>In this cohort, the molecular profile mirrors other Caucasian series, with clinically relevant enrichment patterns for EGFR and KRAS. ECOG performance status and first line treatment were the dominant prognostic factors in this cohort. A novel KRAS and smoking interaction for overall survival warrants prospective validation.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"48 ","pages":"Article 101310"},"PeriodicalIF":3.5,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148583510","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"BRAF V600E Co-mutations predict aggressive clinicopathological features in Chinese patients with differentiated thyroid cancer: A multicenter cohort study","authors":"Jing Du,&nbsp;Bo Guo,&nbsp;Yunpeng Zhang,&nbsp;Songyan Guo,&nbsp;Fan Yang","doi":"10.1016/j.ctarc.2026.101356","DOIUrl":"10.1016/j.ctarc.2026.101356","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Background&lt;/h3&gt;&lt;div&gt;The &lt;em&gt;BRAF &lt;sup&gt;V600E&lt;/sup&gt;&lt;/em&gt; mutation is a common driver variant in differentiated thyroid carcinoma (DTC); however, the clinical significance of its co-mutation patterns in the Chinese population remains unclear. This study aimed to analyze the predictive value of &lt;em&gt;BRAF &lt;sup&gt;V600E&lt;/sup&gt;&lt;/em&gt; co-mutations for aggressive clinicopathological features in DTC by detecting a 10-gene panel, providing molecular evidence for refined risk stratification.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Methods&lt;/h3&gt;&lt;div&gt;A multicenter cohort of 240 DTC patients from two medical centers was retrospectively enrolled. A 10-gene panel (BRAF V600E, TERT, NRAS, HRAS, KRAS, PIK3CA, RET, PPARG, NTRK1, NTRK3) was assessed using Polymerase Chain Reaction (PCR) for mutations and fusion events. Based on mutation status, patients were categorized into three groups: BRAF V600E-mutation alone, BRAF V600E co-mutation, and non-&lt;em&gt;BRAF &lt;sup&gt;V600E&lt;/sup&gt;&lt;/em&gt; mutation groups. Immunohistochemistry (IHC) was performed to evaluate P53 and Ki-67 expression. Clinicopathological characteristics were compared using chi-square, Fisher’s exact, or Kruskal-Wallis tests as appropriate. Log-rank test assessed differences in recurrence-free survival (RFS), while binary/ordinal logistic regression analyzed the predictive role of &lt;em&gt;BRAF &lt;sup&gt;V600E&lt;/sup&gt;&lt;/em&gt; co-mutations for aggressiveness (capsular invasion, ATA risk stratification, lymph node metastasis, and recurrence).&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Results&lt;/h3&gt;&lt;div&gt;The &lt;em&gt;BRAF &lt;sup&gt;V600E&lt;/sup&gt;&lt;/em&gt; co-mutation group (n = 21) exhibited significantly higher rates of capsular invasion (52.4 %vs. 13.2 % and 23.1 %, *p*&lt;0.01) and ATA high-risk classification (57.1 %vs. 25.7 % and 28.8 %, *p*&lt;0.05) compared to the &lt;em&gt;BRAF&lt;sup&gt;V600E&lt;/sup&gt;&lt;/em&gt; -mutation alone group (n = 167) and non-&lt;em&gt;BRAF&lt;sup&gt;V600E&lt;/sup&gt;&lt;/em&gt; mutation group (n = 52). Tumor stage distribution (AJCC 8th edition) also differed significantly among the three groups, with the co-mutation group showing the highest proportion of advanced T stage (T3-T4) (*p*&lt;0.05). &lt;em&gt;TERT&lt;/em&gt; was the most frequently co-mutated gene. Logistic regression revealed that the &lt;em&gt;BRAF&lt;sup&gt;V600E&lt;/sup&gt;&lt;/em&gt; co-mutation group had significantly increased risks of capsular invasion (OR = 3.667, 95 % CI: 1.325–10.713) and ATA high-risk status (OR=2.881, 95 % CI: 1.217–6.839). Although P53/Ki-67 expression did not differ significantly among groups (*p* &gt; 0.05), the co-mutation group showed a trend toward higher proportions of cases with Ki-67 ≥ 10 % (9.5 %vs. 7.2 % and 5.7 %, *p*=0.09).&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Conclusion&lt;/h3&gt;&lt;div&gt;These results suggest that &lt;em&gt;BRAF&lt;sup&gt;V600E&lt;/sup&gt;&lt;/em&gt; co-mutations are associated with more aggressive DTC features in a Chinese patient cohort. The 10-gene panel used in this analysis may offer potential as a tool for identifying subsets of patients with adverse pathology, such that it warrants further investigation as a tool for refined risk stratification. However, ","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"48 ","pages":"Article 101356"},"PeriodicalIF":3.5,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148677479","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Artificial intelligence-powered evaluation of the pathologic response to preoperative therapy in non-small cell lung cancer","authors":"Akira Ono,&nbsp;Takuya Kawata,&nbsp;Mitsuhiro Isaka,&nbsp;Keita Mori,&nbsp;Yohei Shirai,&nbsp;Yujiro Otsuka,&nbsp;Koji Muramatsu,&nbsp;Kiyoshi Tone,&nbsp;Hideyuki Harada,&nbsp;Yasuhisa Ohde,&nbsp;Takashi Sugino,&nbsp;Toshiaki Takahashi","doi":"10.1016/j.ctarc.2026.101355","DOIUrl":"10.1016/j.ctarc.2026.101355","url":null,"abstract":"<div><h3>Introduction</h3><div>Quantitative assessment of the pathologic response (pR) in the eyeball approach remains challenging. Few studies have clearly defined viable tumor cell regions (VTRs). We defined VTRs using AE1/AE3 (AE1/3) staining and examined the usefulness of computational pathology (CP) assessment of the pR after preoperative therapy (PT) in non-small cell lung cancer (NSCLC).</div></div><div><h3>Methods</h3><div>Among 50 NSCLC patients administered PT at our hospital between October 2002 and April 2021, we selected 31 cases that received PT and evaluated the correlations between AI-based and manual assessments of pR on a slide-by-slide in AE1/3 and hematoxylin and eosin (HE) stained slides. A total of 406 virtual slides (vs) were generated and divided into a training set (300 vs) and a test set (58 vs) without case duplication. pR was defined as the percent area of VTRs relative to the total tumor bed (TB) area. An experienced pathologist manually assessed the pR on HE slides and annotated TB regions, which were used to train a TB model. A VTR model was first developed on AE1/3 vs using an algorithm (AE1/3-trained VTR model), and the resulting labels were transferred to the HEvs to train a HE based VTR model (HE-trained VTR model).</div></div><div><h3>Results</h3><div>In the test set, AI assessed pR was strongly correlated with the manually assessed pR in the AE1/3 (Spearman’s ρ, 0.87, 95%CI, 0.74–0.94) and HE vs. (ρ 0.71, 95%CI, 0.49–0.86).</div></div><div><h3>Conclusion</h3><div>The AI-based CP platform appears to be feasible for quantitative evaluation of the pR following PT in cases of NSCLC.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"48 ","pages":"Article 101355"},"PeriodicalIF":3.5,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148688520","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Role of non-animal 3D models in H. pylori associated gastric carcinogenesis: Insights and future perspectives","authors":"Randhir Singh,&nbsp;Dyumn Dwivedi,&nbsp;Anshu Yadav,&nbsp;Maya Chaturvedi,&nbsp;Sourabh Tyagi,&nbsp;Hemant Ritturaj Kushwaha,&nbsp;Rupesh Chaturvedi,&nbsp;Shruti Mishra","doi":"10.1016/j.ctarc.2026.101363","DOIUrl":"10.1016/j.ctarc.2026.101363","url":null,"abstract":"<div><div>Three-dimensional (3D) gastric organoids have become valuable experimental models for gastric cancer research, as they closely mirror tumour architecture, molecular features, and treatment responses. Unlike two-dimensional cultures and animal models, gastric organoids capture key physiological and pathological characteristics of the human stomach, allowing more meaningful investigation of tumour development, host–microbe interactions, and epithelial–stromal crosstalk. These systems retain the genetic and phenotypic traits of their tissue of origin, making them suitable for both mechanistic studies and long-term experimentation.</div><div>This review outlines the development of gastric organoid technology, from early advances in adult stem cell–derived cultures to recent methodological refinements that have expanded their experimental and clinical relevance. We discuss how organoid models have helped address the challenge posed by the marked molecular and histological heterogeneity of gastric cancer, which continues to complicate diagnosis and therapeutics. In this regard, patient-derived gastric organoids and associated biobanks have shown strong potential as predictive tools for drug response, as they reliably preserve tumour structure and gene expression patterns observed in primary tissues. In addition, we highlight recent improvements in culture matrices and experimental approaches that have enhanced organoid robustness and reproducibility. The growing use of gastric organoids as preclinical platforms for drug screening and the study of cancer-related signaling pathways reflects the rapid maturation of the field. We consider current limitations, technical challenges, and future directions for gastric organoid research, emphasizing their role as complementary models that bridge the gap between conventional in vitro systems and in vivo studies in gastric cancer.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"48 ","pages":"Article 101363"},"PeriodicalIF":3.5,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148757261","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Influence of metastatic patterns and initial disease burden on progression- free and survival outcomes in metastatic breast cancer","authors":"Francesca Albrecht,&nbsp;Martin Heidinger,&nbsp;Tibor A. Zwimpfer,&nbsp;Bich Doan Nguyen-Sträuli,&nbsp;Andreas Schoetzau,&nbsp;Marcus Vetter,&nbsp;Christian Kurzeder,&nbsp;Walter P. Weber,&nbsp;Viola Heinzelmann-Schwarz,&nbsp;Fabienne D. Schwab","doi":"10.1016/j.ctarc.2026.101361","DOIUrl":"10.1016/j.ctarc.2026.101361","url":null,"abstract":"<div><h3>Purpose</h3><div>The relationship between the number of initial metastases and metastatic spread in terms of progression-free survival (PFS) and overall survival (OS) in metastatic breast cancer (mBC) remains poorly understood. This study aimed to identify key factors influencing disease progression and survival from the first metastatic manifestation.</div></div><div><h3>Methods</h3><div>This retrospective, single center cohort study included 126 patients with breast cancer and distant metastasis treated at the University Hospital Basel, Switzerland, between 2014 and 2023. We assessed risk factors including metastatic pattern (single metastasis [SM] vs. multiple metastases [MM]), receptor status, histological subtype, and age. Disease progression from the first to second metastatic event was evaluated using the Kaplan-Meier method and log-rank test. Statistical analysis was performed using R software.</div></div><div><h3>Results</h3><div>Patients with SM exhibited significantly better PFS compared to those with MM (HR 2.11, 95% CI 1.38–3.24). Non-triple-negative breast cancer (non-TNBC) patients had superior PFS compared to those with TNBC (HR 2.61, 95% CI: 1.53–4.44). In terms of OS, SM patients had a significantly better outcome compared to MM patients (HR 2.39, 95% CI 1.43–3.99). Additionally, non-TNBC patients showed a significantly better OS than TNBC patients (HR 3.93, 95% CI: 2.2–7).</div></div><div><h3>Conclusions</h3><div>The extent of initial metastasis and TNBC status play a crucial role in determining prognosis in mBC. These factors are essential for predicting disease progression, guiding individualized treatment strategies, and informing ongoing discussions on optimal treatment approaches for patients with oligometastatic breast cancer.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"48 ","pages":"Article 101361"},"PeriodicalIF":3.5,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148757347","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}